Exploratory Associations of Systemic Inflammatory Markers and Prostate Volume with Predominant Gleason Pattern in Gleason Score 7 Prostate Cancer
This exploratory study of 26 patients suggests that combining the neutrophil-to-lymphocyte-to-platelet ratio (NLPR) with prostate volume may offer preliminary, though unvalidated, utility in distinguishing between Gleason 3+4 and 4+3 prostate cancers, warranting further investigation in larger cohorts.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Prostate cancer is a disease where cells in the prostate gland, a small organ in men that produces fluid for semen, begin to grow out of control. Not all prostate cancers are the same; some grow slowly and cause few problems, while others are aggressive and spread quickly. To help doctors decide how to treat a patient, pathologists look at the cancer cells under a microscope and assign them a score based on how abnormal they look. This is called the Gleason score. A score of seven is a middle ground, but it is a tricky one because it is made up of two different patterns mixed together. One pattern, called 3 plus 4, is mostly made of the less dangerous cells, while the other, 4 plus 3, contains more of the aggressive cells. Even though both add up to seven, the 4 plus 3 version is known to be more likely to return after treatment or cause serious problems later. The challenge for doctors is that before surgery or radiation, it is very hard to tell which of these two versions a patient has without cutting out the entire gland to look at it. Finding a simple, non-invasive way to spot the difference could help tailor treatment plans more accurately.
Researchers at the People's Hospital of Xinjiang Uygur Autonomous Region in China set out to see if they could find clues in the blood or the size of the prostate to make this distinction. They focused on two types of information that are already part of standard medical checkups: the size of the prostate gland and the levels of certain cells in the blood that signal inflammation. Inflammation is the body's natural response to injury or infection, but it can also be stirred up by tumors. The team looked at twenty-six men who had already been diagnosed with Gleason score seven cancer. They divided these men into two groups based on their final pathology: fifteen men had the less aggressive 3 plus 4 type, and eleven men had the more aggressive 4 plus 3 type. The researchers measured the volume of each man's prostate using an ultrasound probe inserted into the rectum, a standard procedure that calculates size based on width, length, and height. They also took blood samples to count the numbers of white blood cells, specifically neutrophils, lymphocytes, monocytes, and platelets. From these counts, they calculated several ratios, which are simple math comparisons between different cell types, to see if the balance of these immune cells differed between the two groups.
When the team compared the two groups, they found that the men with the more aggressive 4 plus 3 cancer tended to have slightly larger prostates and a different balance of blood cells, specifically a higher ratio involving neutrophils, lymphocytes, and platelets. However, because the group of patients was so small, these differences were not strong enough to be considered statistically proven facts on their own. The researchers tested how well these individual measurements could separate the two types of cancer. The size of the prostate and the specific blood cell ratio they called the neutrophil-to-lymphocyte-to-platelet ratio showed the most promise, acting as the best single clues available in this small group. When the researchers combined the prostate size with this blood ratio, and then added another inflammation marker called the systemic immune-inflammation index, the ability to distinguish between the two cancer types improved further. In their analysis, this combination of three factors created a model that appeared to separate the groups better than any single test could.
Despite these encouraging numbers, the authors are very careful not to claim they have found a new diagnostic tool. They emphasize that their study was exploratory, meaning it was a first look at a possibility rather than a final answer. The group of twenty-six patients is too small to rule out the chance that the results happened by random luck. The researchers explicitly state that their findings should be viewed as a hypothesis to be tested, not as a rule for doctors to follow today. They note that other common blood markers and prostate density calculations did not help distinguish between the two types of cancer in their study. The main takeaway is that there is a hint of a biological difference between the two forms of Gleason seven cancer that might be visible in the blood and the size of the gland, but this hint needs to be confirmed in much larger studies involving many more patients from different hospitals before it can be trusted. Until then, these observations remain a suggestion for future research rather than a solution for current patients.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.